<DOC>
	<DOCNO>NCT00162019</DOCNO>
	<brief_summary>The purpose study evaluate whether IMMUNATE S/D effective safe treatment hemophilia A patient . The study consist 3 part : Part 1 pharmacokinetic comparison IMMUNATE S/D predecessor IMMUNATE . Part 2 evaluation efficacy safety IMMUNATE S/D . Part 3 pharmacokinetic study IMMUNATE S/D .</brief_summary>
	<brief_title>Pharmacokinetics , Efficacy Safety Study IMMUNATE SD ( Human Plasma-Derived Coagulation Factor VIII Concentrate ) Hemophilia A Patients</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Plasma factor VIII level follow : Parts 1 &amp; 3 : Subjects severe hemophilia A ( plasma baseline factor VIII level &lt; = 1 % measured time screen ) Part 2 : Subjects severe ( plasma baseline factor VIII level &lt; = 1 % measured time screen ) moderately severe hemophilia A ( plasma baseline factor VIII level &lt; = 2 % measured time screen ) Males &gt; = 12 &lt; = 65 year age &gt; = 35 kg body weight Previously treat factor VIII concentrate ( ) minimum 150 exposure day ( documented subject 's medical history ) Evidence protective titer HAV HBV time screen Immunocompetent define CD4+ lymphocyte count &gt; 400/mm3 absolute neutrophil count ( ANC ) &gt; 1500 Signed inform consent obtain subject legally authorize representative Documented history inhibitor factor VIII titer &gt; = 0.8 BU Current evidence inhibitor factor VIII titer &gt; = 0.8 BU , measure time screen Abnormal renal function ( serum creatinine &gt; 1.5 mg/dL ) HIVseropositive individual follow time screen : CD4+ lymphocyte count &gt; 400/mm3 AIDSrelated complex symptomatic AIDS Note : HIVseropositive subject absolute CD4+ lymphocyte count &gt; 400/mm3 eligible participate . HIVseropositive subject receive highly active antiretroviral therapy ( HAART ) regimens eligible enrollment exclude criterion Active hepatic disease ( ALT AST level &gt; 5 time upper limit normal ) Clinical laboratory evidence hepatic cirrhosis include ( limited ) recent persistent INR ( international normalize ratio ) &gt; 1.4 , presence splenomegaly and/or significant spider angioma physical exam , and/or history esophageal hemorrhage document esophageal varix Known hypersensitivity IMMUNATE The subject currently participate another investigational drug study , participate clinical study involve investigational drug within 30 day study entry The subject currently receive , schedule receive course study , immunomodulating drug antiretroviral chemotherapy ( e.g. , ainterferon , steroid dose great 10 mg/day ) The subject identify investigator unable unwilling perform study procedure</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Factor VIII Deficiency</keyword>
</DOC>